Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study.
Article in JMIR cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
32 authors.
Maitri KalraDivision of Hematology/Oncology, Department of Medicine, Indiana University Health Ball Memorial Hospital, Fishers, IN, United States.ORCID 0000-0002-6635-6152
Elizabeth HenryDivision of Hematology/Oncology, Department of Medicine, Loyola University Stritch School of Medicine, Maywood, IL, United States.ORCID 0000-0003-2948-3985
Kelly McCannDivision of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Beverly Hills, CA, United States.ORCID 0000-0001-8233-6242
Meghan S KaruturiDivision of Hematology/Oncology, Department of Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.ORCID 0000-0001-8795-3901
Jean G Bustamante AlvarezDivision of Hematology/Oncology, Department of Medicine, West Virginia University, Morgantown, WV, United States.ORCID 0000-0002-5499-3621
Amanda ParkesDivision of Hematology/Oncology, Department of Medicine, University of Wisconsin, Madison, WI, United States.ORCID 0000-0002-2599-6460
Robert WesolowskiDivision of Hematology/Oncology, Department of Medicine, Ohio State University, Columbus, OH, United States.ORCID 0000-0003-0606-0648
Mei WeiDivision of Hematology/Oncology, Department of Medicine, University of Utah, Utah City, UT, United States.ORCID 0000-0003-4411-1178
Sarah S MougalianDepartment of Radiation/Oncology, Yale University School of Medicine, New Haven, CT, United States.ORCID 0000-0002-8837-1425
Gregory DurmDivision of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, United States.ORCID 0000-0003-2606-745X
Angel QinDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States.ORCID 0000-0002-0339-3087
Caitlin SchonewolfDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States.ORCID 0000-0003-0341-9977
Meghna TrivediDivision of Hematology/Oncology, Department of Medicine, Herbert-Irving Comprehensive Cancer Center, Columbia University, New York, NY, United States.ORCID 0000-0002-4831-0492
Avan J ArmaghaniDivision of Hematology/Oncology, Department of Medicine, Moffitt Cancer Center University of South Florida, Tampa, FL, United States.ORCID 0000-0002-5426-3119
Frederick H WilsonDepartment of Radiation/Oncology, Yale University School of Medicine, New Haven, CT, United States.ORCID 0000-0002-5019-0186
Wade T IamsDivision of Oncology, Department of Medicine, Vanderbilt University, Nashville, TN, United States.ORCID 0000-0003-2109-298X
Anita A TurkDivision of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, United States.ORCID 0000-0002-4159-5376
Praveen VikasDivision of Hematology/Oncology, Department of Medicine, University of Iowa, Iowa City, IA, United States.ORCID 0000-0001-9193-9889
Michael CecchiniDepartment of Radiation/Oncology, Yale University School of Medicine, New Haven, CT, United States.ORCID 0000-0003-3504-0128
Sam LubnerDivision of Hematology/Oncology, Department of Medicine, University of Wisconsin, Madison, WI, United States.ORCID 0000-0002-5732-2938
Priyadarshini PathakDivision of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, United States.ORCID 0000-0003-2116-5528
Kristen SpencerDivision of Hematology/Oncology, Department of Medicine, Rutgers University Cancer Institute of New Jersey, New Brunswick, NJ, United States.ORCID 0000-0001-5577-3439
Vadim S KoshkinDivision of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Beverly Hills, CA, United States.ORCID 0000-0003-2277-8668
Matthew K LabriolaDivision of Hematology/Oncology, Department of Medicine, Duke University, Durham, NC, United States.ORCID 0000-0003-0919-9864
Catherine H MarshallDivision of Oncology, Department of Medicine, Johns Hopkins University, Baltimore, MD, United States.ORCID 0000-0002-2653-4110
Katy E BeckermannDivision of Oncology, Department of Medicine, Vanderbilt University, Nashville, TN, United States.ORCID 0000-0002-4616-6140
theMednet.org NCI-CCC Tumor Board Program Collaborative Group *Mednet Inc, New York, NY, United States.
Marina N SharifiDivision of Hematology/Oncology, Department of Medicine, University of Wisconsin, Madison, WI, United States.ORCID 0000-0003-0128-3033
Anthony C BejjaniDivision of Hematology/Oncology, Department of Medicine, Veterans Health Administration Greater Los Angeles Health System, Los Angeles, CA, United States.ORCID 0000-0003-2241-6974
Nadine HousriDepartment of Radiation/Oncology, Yale University School of Medicine, New Haven, CT, United States.ORCID 0000-0001-7447-4223
Funding
Vanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9M
YALE CANCER CENTER CALABRESI IMMUNO-ONCOLOGY TRAINING PROGRAMK12CA215110 · NCI · YALE UNIVERSITY · PI Harriet M. Kluger · 2018 to 2026
$6.1M
Immunomodulatory Effects of Targeting DNA Repair with Novel Temozolomide Combinations in Colorectal CancerK08CA255465 · NCI · YALE UNIVERSITY · PI CECCHINI, MICHAEL · 2021 to 2025
backgroundExpert knowledge is often shared among multidisciplinary academic teams at tumor boards (TBs) across the country, but these conversations exist in silos and do not reach the wider oncology community.
objectiveUsing an oncologist-only question and answer (Q&A) website, we sought to document expert insights from TBs at National Cancer Institute-designated Comprehensive Cancer Centers (NCI-CCCs) to provide educational benefits to the oncology community.
methodsWe designed a process with the NCI-CCCs to document and share discussions from the TBs focused on areas of practice variation on theMednet, an interactive Q&A website of over 13,000 US oncologists. The faculty translated the TB discussions into concise, non-case-based Q&As on theMednet. Answers were peer reviewed and disseminated in email newsletters to registered oncologists. Reach and engagement were measured. Following each Q&A, a survey question asked how the TB Q&As impacted the readers' practice.
resultsA total of 23 breast, thoracic, gastrointestinal, and genitourinary programs from 16 NCI-CCC sites participated. Between December 2016 and July 2021, the faculty highlighted 368 questions from their TBs. Q&As were viewed 147,661 times by 7381 oncologists at 3515 institutions from all 50 states. A total of 277 (75%) Q&As were viewed every month. Of the 1063 responses to a survey question on how the Q&A affected clinicians' practices, 646 (61%) reported that it confirmed their current practice, 163 (20%) indicated that a Q&A would change their future practice, and 214 (15%) reported learning something new.
conclusionsThrough an online Q&A platform, academics at the NCI-CCCs share knowledge outside the walls of academia with oncologists across the United States. Access to up-to-date expert knowledge can reassure clinicians' practices, significantly impact patient care in community practices, and be a source of new knowledge and education.
Indexed as
cancerdigital healthhealth educationhealth websitesknowledge sharingNational Cancer Institute–designated Comprehensive Cancer CentersNCI-CCConcologyTBstumor boards
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study. · full record | OpenQuestion